NxStage Medical Inc. (NXTM) Stock Price Down 0.6%
NxStage Medical Inc. (NASDAQ:NXTM) fell 0.6% during trading on Monday . The stock traded as low as $22.55 and last traded at $22.77, with a volume of 424,927 shares. The stock had previously closed at $22.91.
Several research firms have commented on NXTM. Wells Fargo & Co. reiterated a “sell” rating on shares of NxStage Medical in a research note on Thursday, May 5th. Canaccord Genuity reiterated a “buy” rating on shares of NxStage Medical in a research note on Wednesday, May 4th. Zacks Investment Research upgraded NxStage Medical from a “strong sell” rating to a “hold” rating in a research report on Wednesday, May 4th. Piper Jaffray Cos. restated a “buy” rating and issued a $21.00 price target on shares of NxStage Medical in a research report on Friday, June 3rd. Finally, Northland Securities upgraded NxStage Medical from a “market perform” rating to an “outperform” rating and set a $25.00 price target for the company in a research report on Tuesday, June 28th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $24.50.
The firm’s market capitalization is $1.47 billion. The firm has a 50-day moving average of $20.26 and a 200 day moving average of $17.67.
NxStage Medical (NASDAQ:NXTM) last announced its quarterly earnings results on Wednesday, May 4th. The medical device company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.03. The business had revenue of $89.20 million for the quarter, compared to analysts’ expectations of $88.40 million. During the same period last year, the company posted ($0.09) earnings per share. The firm’s revenue for the quarter was up 12.2% on a year-over-year basis. Equities research analysts anticipate that NxStage Medical Inc. will post ($0.12) EPS for the current fiscal year.
In other NxStage Medical news, President Joseph E. Turk, Jr. sold 2,000 shares of the business’s stock in a transaction on Thursday, April 21st. The shares were sold at an average price of $15.73, for a total value of $31,460.00. Following the transaction, the president now owns 104,780 shares in the company, valued at approximately $1,648,189.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Winifred L. Swan sold 6,260 shares of the business’s stock in a transaction on Thursday, April 14th. The stock was sold at an average price of $16.40, for a total transaction of $102,664.00. Following the completion of the transaction, the senior vice president now owns 15,734 shares in the company, valued at approximately $258,037.60. The disclosure for this sale can be found here.
Other institutional investors have recently modified their holdings of the company. Rhumbline Advisers raised its position in shares of NxStage Medical by 8.3% in the fourth quarter. Rhumbline Advisers now owns 68,426 shares of the medical device company’s stock worth $1,499,000 after buying an additional 5,240 shares in the last quarter. OppenheimerFunds Inc. raised its position in shares of NxStage Medical by 2.0% in the fourth quarter. OppenheimerFunds Inc. now owns 728,153 shares of the medical device company’s stock worth $15,954,000 after buying an additional 14,578 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of NxStage Medical by 6.5% in the fourth quarter. Wells Fargo & Company MN now owns 1,450,307 shares of the medical device company’s stock worth $31,777,000 after buying an additional 88,286 shares in the last quarter. Tamarack Advisers LP purchased a new position in shares of NxStage Medical during the fourth quarter worth approximately $42,177,000. Finally, EAM Investors LLC raised its position in shares of NxStage Medical by 27.7% in the fourth quarter. EAM Investors LLC now owns 190,285 shares of the medical device company’s stock worth $4,169,000 after buying an additional 41,220 shares in the last quarter.
NxStage Medical, Inc is a medical device company. The Company is engaged in the development, manufacturing and marketing of products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s products include the System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.